Owners, management and financials
CVR: 39507056
DKK -10,750
Gross profit
Net result: DKK -26,512
SPORCON LIFESCIENCE ADVISORS ApS (10-14,99%), HDJ & LEJ Invest ApS (90-99,99%)
CVR · view owners
Hanne Damgaard Jensen
CVR · view management
Active
Founded 23 April 2018
CVR · view overview
0 employees
Annual report 2025 · average
Owner registered: HDJ & LEJ Invest ApS
CVR · 11/09/2025
View the full event history
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
Selskabets formål er at investere samt anden virksomhed, der står i forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -11 t. | -27 t. | 40 t. | -117 t. | 0 | |
| 202401/01/2024 – 31/12/2024 | -13 t. | -14 t. | 19 t. | -256 t. | 1 | |
| 202301/01/2023 – 31/12/2023 | -13 t. | -14 t. | 26 t. | -243 t. | 1 | |
| 202201/01/2022 – 31/12/2022 | -13 t. | -14 t. | 35 t. | -229 t. | 1 | |
| 202101/01/2021 – 31/12/2021 | -13 t. | -4.3 mio. | 34 t. | -225 t. | 1 | |
| 202001/01/2020 – 31/12/2020 | -13 t. | 4 mio. | 4.3 mio. | 4.1 mio. | 1 | |
| 201901/01/2019 – 31/12/2019 | -15 t. | -12 t. | 4.3 mio. | 66 t. | 1 |
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of ROS Therapeutics Holding ApS is 39507056.
ROS Therapeutics Holding ApS is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS.
The management of ROS Therapeutics Holding ApS consists of Hanne Damgaard Jensen.
In 2025, ROS Therapeutics Holding ApS reported a gross profit of DKK -10,750.
ROS Therapeutics Holding ApS had an average of 0 employees in the 2025 financial year according to the annual report.
ROS Therapeutics Holding ApS was founded on 23 April 2018.
Claim this page to add your logo and social links. Free to get started.
ROS Therapeutics Holding ApS has published its annual report for 2025. Gross profit came to DKK -10,750, and the net result was DKK -26,512.
As of September 11, 2025, HDJ & LEJ Invest ApS is registered as an owner of ROS Therapeutics Holding ApS with an ownership share of 90%.
ROS Therapeutics Holding ApS has published its annual report for 2024. Gross profit came to DKK -12,875, and the net result was DKK -14,342.
ROS Therapeutics Holding ApS has published its annual report for 2023. Gross profit came to DKK -12,500, and the net result was DKK -13,845.
ROS Therapeutics Holding ApS has published its annual report for 2022. Gross profit came to DKK -12,500, and the net result was DKK -13,879.
ROS Therapeutics Holding ApS has published its annual report for 2021. Gross profit came to DKK -12,500, and the net result was DKK -4,284,829.
ROS Therapeutics Holding ApS has published its annual report for 2020. Gross profit came to DKK -12,500, and the net result was DKK 3,990,250.
ROS Therapeutics Holding ApS has published its annual report for 2019. Gross profit came to DKK -15,000, and the net result was DKK -11,963.
As of May 10, 2020, SPORCON LIFESCIENCE ADVISORS ApS is registered as an owner of ROS Therapeutics Holding ApS with an ownership share of 10%.
As of June 24, 2019, Hanne Damgaard Jensen has left the board of directors of ROS Therapeutics Holding ApS.
As of June 24, 2019, Mads Hartvig Clausen has left the board of directors of ROS Therapeutics Holding ApS.
As of June 24, 2019, Jon Bondebjerg has left the board of directors of ROS Therapeutics Holding ApS.
ROS Therapeutics Holding ApS has published its interim report for the period April 23, 2018 – December 31, 2018.
As of October 31, 2018, Christian Philip Hansen has left the board of directors of ROS Therapeutics Holding ApS.
As of April 23, 2018, Hanne Damgaard Jensen has joined the board of directors of ROS Therapeutics Holding ApS.
As of April 23, 2018, Christian Philip Hansen has joined the board of directors of ROS Therapeutics Holding ApS.
As of April 23, 2018, Mads Hartvig Clausen has joined the board of directors of ROS Therapeutics Holding ApS.
As of April 23, 2018, Jon Bondebjerg has joined the board of directors of ROS Therapeutics Holding ApS.
As of April 23, 2018, Hanne Damgaard Jensen is registered as director of ROS Therapeutics Holding ApS.
ROS Therapeutics Holding ApS was founded on April 23, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 10370671
CVR 33596200
CVR 31065372
CVR 29246416
CVR 30531639
